Camurus AB (CAMX.ST) Stock Analysis & Winston Score

Camurus is a Swedish pharmaceutical company that develops and sells prescription medicines for serious, long-term conditions like opioid addiction, cancer pain, and hormone disorders. Its most important product is Brixia (also sold as Buvidal), a long-acting injectable treatment for opioid dependence that patients receive weekly or monthly instead of taking a daily pill. The company sells primarily to hospitals, clinics, and addiction treatment centers across Europe, Australia, and the United States. Camurus makes money by selling its medicines directly and through licensing partnerships with larger pharmaceutical companies in certain markets. It is headquartered in Lund, Sweden, and operates mainly across Europe and other developed markets, with the United States representing a growing opportunity. Its core competitive advantage is a proprietary drug-delivery technology called FluidCrystal, which allows medicines to release slowly inside the body over days or weeks — a format that is difficult for competitors to replicate. The key growth driver is expanding Buvidal's adoption in the large and underpenetrated U.S. opioid treatment market.